Li-Fraumeni syndrome - A molecular and clinical review

British Journal of Cancer

Volumn 76, Issue 1, 1997, Pages 1-14

  Varley, J M ^a   Evans, D G R ^a   Birch, J M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GENETICS; FAMILIAL CANCER; GENE MUTATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0030957152     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.328     Document Type: Review

References (147)

1. Armstrong JF, Kaufman MH, Harrison DJ and Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5: 937-943
2. Arrowsmith CH and Morin P (1996) New insights into p53 function from structural studies. Oncogene 12: 1379-1385
3. Bang YJ, Kang SH. Kim TY, Jung CW, Oh SM, Choe KJ and Kim NK (1995) The first documentation of Li-Fraumeni syndrome in Korea. J Korean Med Sci 10: 205-210
4. Barnes DM, Hanhy AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, MacGeoch C, Spurr NK, Bartek J, Vojtesek B, Picksley SM and Lane DP (1992) Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient. Lancet 340: 259-263
5. Bech-Hansen NT, Blattner WA, Sell BM, McKee EA, Lampkin BC, Fraumeni JF and Paterson MC (1981) Transmission of in vitro radioresistance in a cancer-prone family. Lancet 1: 1335-1337
6. Birch JM (1994) Li-Fraumeni syndrome. Eur J Cancer 30A: 1935-1941
7. Birch JM, Hartley AL, Marsden HB, Harris M and Swindell R (1984) Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 49: 325-331
8. Birch JM, Hartley AL, Blair V, Kelsey AH, Harris M, Teare MD and Morris Jones PH (1990) Cancer in the families of children with soft tissue sarcomas. Cancer 66: 2237-2248
9. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD and Santibanez-Koref MF (1994a) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298-1304
10. Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP and Santibanez-Koref MF (1994b) Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70: 1176-1181
11. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC and Tainsky MA (1990) Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50: 7979-7984
12. Børresen A-L, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D and Friend SH (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234-3236
13. Bouffler SD, Kemp CJ, Balmain A and Cox R (1995) Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 55: 3883-3889
14. Brugières L, Gardes M, Moutou C, Chompret A, Meresse V, Martin A, Poisson N, Flamant F, Bonaïti-Pellié C, Lemerle J and Feunteun J (1993) Screening for germ line p53 mutations in children with malignant tumours and a family history of cancer. Cancer Res 53: 452-455
15. Camplejohn RS, Perry P, Hodgson SV, Turner G, Williams A, Upton C, MacGeoch C, Mohammed S and Barnes DM (1995) A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Hr J Cancer 72: 654-662
16. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC and White RL (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779-784
17. Chen P, Iavarone A, Fick J, Edwards M, Prados M and Israel MA (1995) Constitutional p53 mutations associated with brain tumors in young adults. Cancer Genet Cytogenet 82: 106-115
18. Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355
19. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Heitlich C, Freiman R, Hedley-White ET, Martuza R, Jenkins R, Yandell D and Seizinger BR (1991) TP53 gene mutations and 17p deletions in human astrocytomas Genes Chrom Cancer 3: 323-331
20. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E and Gronenborn AM (1994) High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265: 386 391
21. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356
22. Diller L, Sexsmith E, Gottlieb A, Li FP and Malkin D (1995) Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95: 1606-1611
23. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS and Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
24. Easton D, Ford D and Peto J (1993) Inherited susceptibility to breast cancer. Cancer Surv 18: 95-113
25. Eeles RA (1993) Predictive testing for germline mutations in the p53 gene: are all the questions answered? Eur J Cancer 29A: 1361-1365
26. Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surg 25: 101-123
27. Eeles RA, Warren W, Knee G, Bartek J, Averill D, Stratton MR, Blake PR, Tait DM, Lane DP, Easton DF, Yarnold JR, Cooper CS and Sloane JP (1993) Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 8: 1269-1276
28. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genet 1: 45-49
29. Eliyahu D, Raz A, Gruss P, Givol D and Oren M (1984) Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312: 646-649
30. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T and Minna JD (1992) Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89: 640-647
31. Felix CA, Strauss EA, D'Amico D, Tsokos M, Winter S, Mitsudomi T, Nan MM, Brown DL, Leahey AM, Horowitz ME, Poplack DG, Costin D and Minna JD (1993) A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene 8: 1203-1210
32. Felix CA, Slave I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR and Biegel JA (1995) p53 gene mutations in pediatric brain tumors. Med Pediat Oncol 25: 431-436
33. Felix CA, Hosler MR, Provisor D, Salhany K, Sexsmith EA, Slater DJ, Cheung N-KV, Winick NJ, Strauss EA, Heyn R, Lange BJ and Malkin D (1996) The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 87: 4376-4381
34. Fields S and Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1048
35. Finlay CA, Hinds PW and Levine AJ (1989) The p53 proto-oneogene can act as a suppressor of transformation. Cell 57: 1083-1093
36. Flaman J-M, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino A-P, Limacher J-M, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A and lggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumours. Proc Natl Acad Sci USA 92: 3963-3967
37. Ford JM and Hanawalt PC (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc Natl Acad Sci USA 92: 8876-8880
38. Frebourg T, Barbier N, Kassel J, Ng Y-S, Romero P and Friend SH (1992) A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 52: 6976-6978
39. Frebourg T, Barbier N, Yan Y, Garber JE, Dreyfus M, Fraumeni J, Li FP and Friend SH (1995) Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56: 608-615
40. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF and Li FP (1991) Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51: 6094-6097
41. Grayson CH, Moore S, Schneider BG. Saldivar V and Hensel CH (1994) Novel germline mutation of the p53 tumor suppressor gene in a child wilh incidentally discovered adrenal cortical carcinoma. Am J Pediatr Hematol Oncol 16: 341-347
42. Greenblatt MS, Bennelt WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
43. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V and Barkardottir R (1995) Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 55: 4830-4832
44. Gutierrez MI, Bhatia KG, Barreiro C, Spangler G, Schvartzmann E, Muriel FS and Magrath IT (1994) A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors. Hum Mol Genet 3: 2247-2248
45. Hamelin R, Barichard F, Henry I, Junien C and Thomas G (1994) Single base pair germ-line deletion in the p53 gene in a cancer predisposed family. Hum Genet 94: 88-90)
46. Harris CC (1996) The 1995 Walter Hubert lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 73: 261-269
47. Hartley AL, Birch JM, Marsden HB and Harris M (1987) Malignant melanoma in families of children with osteosarcoma, chondrosarcoma and adrenal cortical carcinoma. J Med Genet 24: 664-668
48. Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M and Teare MD (1989) Are germ cell tumours part of the Li-Fraumeni cancer family syndrome. Cancer Genet Cytogenet 42: 221-226
49. Harvey M, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A and Donehower LA (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet 5: 225-229
50. Heyn R, Haeberlen V, Newton WA, Ragab AH, Raney B, Teffi M, Wharam M, Ensign LG and Maurer HM (1993) Second malignant neoplasms in children treated for rhabdomyosarcoma. J Clin Oncol 11: 262-270
51. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
52. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R and Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids. Res 24: 141-146
53. Horio Y, Suzuki H, Ueda R, Koshikawa T, Sugiura T, Ariyoshi Y, Shimokata K, Takahashi T and Takahashi T (1994) Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9: 1231-1235
54. Iavarone A, Matlhay KK, Steinkirchner TM and Israel MA (1992) Germ-line and somatic p53 mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89: 4207-4209
55. Ichii S, Horii A, Nakatsuru S, Furuyania J, Ulsunomiya J and Nakamura Y (1992) Inactivation of both APC alleles in an early stage of colon adenomas in a patient with familial adenomatous polyposis (FAP). Hum Mol Genet 1: 387-390
56. Ishioka C, Frebourg T, Yan Y-X, Vidal M, Friend SH, Schmidt S and lggo R (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet 5: 124-129
57. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA (1994) Tumor spectrum analysis in P53-deficient mice. Curr Biol 4: 1-7
58. Jeffrey PD, Gorina S and Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498-1502
59. Jenkins JR, Rudge K and Currie GA (1984) Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312: 651-654
60. Jenkins JR, Rudge K, Chumakov P and Currie GA (1985) The cellular oncogene p53 can be activated by mutagenesis. Nature 317: 816-818
61. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE and Look AT (1994) Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 9: 97-102
62. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
63. Kemp CJ, Wheldon T and Balmain A (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet 8: 66-69
64. Knudson AG, Jr (1971) Mutation and cancer: statistical study of relinoblastoma. Proc Natl Acad Sci USA 68: 820-823
65. Kovar H, Auinger A, Jug G, Müller T and Pillwein K (1992) p53 mosaicism with an exon 8 germline mutation in the founder of a cancer-prone family. Oncogene 7: 2169-2173
66. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
67. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA and Saya H (1994) Germline p53 mutations in subsets of glioina patients. J Natl Cancer Inst 86: 344-349
68. Lalle P, Moyret-Lalle C, Wang Q, Vialle J-M, Navarro C, Bressac-de Paillerets B, Magaud J-P and Ozturk M (1995) Genomic instability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene 10: 2447-2454
69. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
70. Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40 transformed cells. Nature 278: 261-263
71. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T and Bernstein A (1989) High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9: 3982-3991
72. Law JC, Strong LC, Chidambaram A and Ferrell RE (1991) A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 51: 6385-6387
73. LeBihan C, Moutou C, Brugières L, Feunteun J and Bonaïti-Pellié C (1995) ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genetic Epidemiol 12: 13-25
74. Lee JM and Bernstein A (1993) p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746
75. Lee JM, Abrahamson JL, Kandel R, Donehower LA and Bernstein A (1994) Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9: 3731-3736
76. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
77. Li FP and Fraumeni JF (1969a) Rhabdomyosarcoma in children; epidemiologic study and identification of a cancer family syndrome. J Natl Cancer Inst 43: 1365-1373
78. Li FP and Fraumeni JF (1969b) Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome? Ann Int Med 71: 747-752
79. Li FP and Fraumeni JF (1982) Prospective study of a cancer family syndrome. JAMA 247: 2692-2694
80. Li FP and Fraumeni JF (1994) Collaborative interdisciplinary studies of p53 and other predisposing mutations in Li-Fraumeni syndrome. Cancer Epidemiology, Biomarkers and Prevention 3:715-717
81. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362
82. Li FP, Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P and Fraumeni JF (1992) Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 84: 1156-1160
83. Li Y-J, Sanson M, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G and Hamelin R (1995) Incidence of germ-line p53 mutations in patients with gliomas. Int J Cancer 64: 383-387
84. Linzer DIH and Levine AJ (1979) Characterisation of a 54, 000 MW cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52
85. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B and Kinzler KW (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nature Med 2: 169-174
86. Liu PK, Kraus E, Wu TA, Strong LC and Tainsky MA (1996) Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene 12: 2267-2278
87. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tisty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935
88. Lomax ME, Barnes DM, Gilchrist R, Picksley SM, Varley JM and Camplejohn RS (1997) An unusual p53 germline mutation in the oligomerisation domain in a Li-Fraumeni-like family. Br J Cancer (in press)
89. Lubbe J, von Ammon K, Watanabe K, Hegi ME and Kleihues P (1995) Familial brain tumour syndrome associated with a p53 germline deletion at codon 236. Brain Pathol 5: 15-23
90. Lustbader ED, Williams WR, Bondy ML, Strom S and Strong LC (1992) Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet 51: 344-356
91. MacGeoch C, Turner G, Bobrow LG, Barnes DM, Bishop DT and Spurr NK (1995) Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining. J Med Genet 32: 186-190
92. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238
93. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Børresen A-L, Li FP, Garber J and Strong L (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326: 1309-1315
94. Mazoyer S, Lalle P, Moyret-Lalle C, Marcais C, Schraub S, Frappaz D, Sobol H and O'zturk M (1994) Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 9: 1237-1239
95. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen A-L, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D and Gebhardt MC (1994) Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12: 925-930
96. Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MSB and Cogen PH (1991) Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc-Natl Acad Sci USA 88: 7825-7829
97. Milner J and Metcalf EA (1991) Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774
98. Nishino H, Knoll A, Buettner VL, Frisk CS, Maruta Y, Haavik J and Sommer SS (1995) p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. Oncogene 11: 263-270
99. Parada LF, Land H, Weinberg RA, Wolf D and Rotter V (1984) Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312: 649-651
100. Parshad R, Price FM, Pirollo KF, Chang EH and Sanford KK (1993) Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res 136: 236-240
101. Paules RS, Levedakou EN, Wilson SJ, Innes CL, Rhodes N, Tlsty T, Galloway DA, Donehower LA, Tainsky MA and Kaufmann WK (1995) Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res 55: 1763-1773
102. Pearson ADJ, Craft AW, Ratcliffe JM, Birch JM, Morris Jones PH and Roberts DF (1982) Two families with the Li-Fraumeni cancer family syndrome. J Med Genet 19: 362-365
103. Plummer SJ, Santibanez-Koref M, Kurosaki T, Liao S, Noble B, Fain PR, AntonCulver H and Casey G (1994) A germline 2.35kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family. Oncogene 9: 3273-3280
104. Ponder BA (1988) Gene losses in human tumours. Nature 335: 400-402
105. Porter DE, Holden ST, Steel CM, Cohen BB, Wallace MR and Reid R (1992) A significant proportion of patients with osteosareoma may belong to Li-Fraumeni cancer families. J Bone Joins Surg 74B: 883-886
106. Prosser J, Porter D, Coles C, Condie A, Thompson AM, Chetty U, Steel CM and Evans HJ (1992) Constitutional p53 mutation in a non-Li-Fraumeni cancer family. Br J Cancer 65: 527-528
107. INK4 expression and telomere length during spontaneous immortalisation of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15: 4745-1753
108. Russo CL, McIntyre J, Goorin AM, Link MP, Gebhardt MC und Friend SH (1994) Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations. Med Pediat Ontol 23: 354-358
109. Sah VP, Attardi LD, Mulligan DJ, Williams BO, Bronson RT and Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nature Genet 10: 175-180
110. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M and Yokota J (1992) Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by screening patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 84: 703-707
111. Sands AT, Suroakar MB, Sanchez A, Marth JE, Donehower LA and Bradley A (1995) p53 deficiency does not affect the accumulation of point mutations in a transgenic target. Proc Natl Acad Sci USA 92: 8517-8521
112. Santibanez-Koref MF, Birch JM, Hartley AL, Jones PH, Craft AW, Eden T, Crowther D, Kelsey AM and Harris M (1991) p53 germline mutations in Li-Fraumeni syndrome. Lancet 338: 1490-1491
113. Schärer E and Iggo R (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20: 1539-1545
114. Schneider KA, Patenaude AF and Garher JE (1995) Testing for cancer genes: decisions, decisions. Nature Med 1: 942-945
115. Scott RJ, Krummenacher F, Mary J-L, Weber W, Spycher M and Muller H (1993) Vererbbare p53-mutation bei einem Patienten mit Mehrfachtumoren: Bedeutung fur die genetische Beratung. Schweiz Med Wochenschr 123: 1287-1292
116. Shay JW, Tomlinson G, Piatyszek MA and Gollahon LS (1995) Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol Cell Biol 15: 425-432
117. Shi Y-P, Venkatachalam S, Junes S, Vogel H, Bradley A, Pinkel D and Donehower LA (1997) Retention of the wild-type allele in tumors from p53-deficient heterozygous mice: is p53 an exception to the two hit hypothesis? Nature Genet (submitted)
118. Shiseki M, Nishikawa R, Yamamoto H, Ochiai A, Sugimura H, Shitara N, Sameshima Y, Mizoguchi H, Sugimura T and Yokota J (1993) Germ-line p53 mutation is uncommon in patients with triple primary cancers. Cancer Lett 73: 51-57
119. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B and Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984-2986
120. Smith SA, Easton DF, Evans DGR and Ponder BAJ (1992) Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 2: 128-131
121. Soussi T, Caron de Fromentel C and May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952
122. Speiser P, Gharehbaghi-Schnell E, Eder S, Haid A, Kovarik J, Nenutil R, Sauter G, Schneeberger CH, Vojtesek B, Wiltschke CH and Zeillinger R (1996) A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer 74: 269-273
123. Sproston ARM, Boyle JM, Heighway J, Birch JM and Scott D (1996) Fibroblasts from Li-Fraumeni patients are resistant to low dose-rate irradiation. Int J Radiat Biol 70: 145-150
124. Srivastava S, Zou Z, Pirollo K, Blattner W and Chang HH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749
125. Srivastava S, Tong YA, Devadas K, Zou Z-Q, Sykes VW, Chen Y, Blattner WA, Pirollo K and Chang EH (1992) Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene 7: 987-991
126. Stewart N, Hicks GG, Paraskevas F and Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115
127. Stolzenberg M-C, Brugières L, Gardes M, Dessarps-Freichey F, Chompret A, Bressac B, Lenoir G, Bonaïti-Pellié C, Lemerle J and Feunteun J (1994) Germline exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni family. Oncogene 9: 2799-2804
128. Strauss FA, Hosler MR, Herzog P, Salhany K, Louie R and Felix CA (1995) Complex replication error causes p53 mutation in a Li-Fraumeni family. Cancer Res 55: 3237-3241
129. Strong LC and Williams WR (1987) The genetic implications of long-term survival of childhood cancer. Am J Pediatr Hematol Oncol 9: 99-103
130. Strong LC, Stine M and Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79: 1213-1220
131. Sun X-F, Johannsson O, Hakansson S, Sellberg G, Nordenskjold B, Olsson H and Borg A (1996) A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13: 407-411
132. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR and Yandell DW (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326: 1301-1308
133. Tory K, Brauch H, Linehan M, Barba D, Oldfeld E, Filling-Katz M, Seizinger B, Nakamura Y, White R, Marshall FF, Lerman MI and Zbar B (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Caner Inst 81: 1097-1101
134. Tsutsui T, Fujino T, Kodama S, Tainsky MA, Boyd J and Barrett JC (1995) Alfatoxin B 1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. Cacinogenesis 16: 25-34
135. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF. Houlston RS, Martin J, Birch JM and Evans DGR (1995) An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 32: 946-950
136. Varley JM, Thorncroft M, McGown G, Tricker K, Birch JM and Evans DGR (1996a) A novel deletion within exon 6 of TP53 in a family with Li Fraumenilike syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 90: 14-16
137. Varley JM, MGown G, Thorncroft M, Cochrane S, Morrison P, Woll P, Kelsey AM. Mitchell ELD. Boyle J, Birch JM and Evans DGR (1996b) A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 12: 2437-2442
138. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KM, Evans DGR and Birch JM (1997a) Germline mutations of TP53 in Li-Fraumeni families: an extended study of 39 families, (submitted)
139. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KM, Evans DGR and Birch JM (1997b) A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14: 865-871
140. Vogelstein B (1990) A deadly inheritance. Nature 348: 681-682
141. Vogelstein B and Kinzler KW (1994) X-rays strike p53 again. Nature 370: 174-175
142. Wagner J, Portwine C, Rabin K, Leclere J-M, Narod SA and Malkin D (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86: 1707-1710
143. Warneford SG, Witton LJ, Townsend ML, Rowe PB, Reddel RR, Dalla-Pozza L and Symonds G (1992) Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Different 3: 839-846
144. Williams KJ, Heighway J, Birch JM, Norton JD and Scott D (1996) No defect in G/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. Br J Cancer 74: 698-703
145. Williams KJ, Boyle JM, Birch JM, Norton JD and Scott D (1997) Cell cycle arrest detect in Li-Fraumeni syndrome: a mechanism of cancer predisposition? Oncogene 14: 277-282
146. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948
147. Yonish-Rouach E. Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347